Posts tagged Phase 2
Ladenburg starts Flex Pharma at buy; PT $12

Ladenburg Thalmann initiated coverage of Flex Pharma (NASDAQ:FLKS) with a “buy” rating and $12 price target. The stock closed at $4.02 on Jan. 24.

Read More
Maxim starts Immune Pharma at buy; PT $3

Maxim Group launched coverage of Immune Pharmaceuticals (NASDAQ:IMNP) with a “buy” rating and $3 price target. The stock closed at 57 cents on Jan. 4.

Read More
Eiger completes enrollment in Phase 2 ULTRA study

Eiger BioPharmaceuticals (NASDAQ:EIGR) completed enrollment of the Phase 2 ULTRA study designed to evaluate the effects of ubenimex in patients with primary and secondary lymphedema of the lower limbs. A total of 54 patients were enrolled across sites in the U.S. and Australia.

Read More
NeuroproteXeon additional Phase 2 data published in JACC

Closely-held NeuroproteXeon announced the publication of a second finding from a randomized, controlled Phase 2 trial of inhaled xenon and oxygen, combined with hypothermia, for out-of-hospital cardiac arrest (OHCA) patients.

Read More
BiondVax, NIAID in Phase 2 trial of universal flu vaccine

BiondVax Pharmaceuticals (NASDAQ, TASE:BVXV) signed a clinical trial agreement for a Phase 2 clinical trial with the NIH’s National Institute of Allergy and Infectious Diseases (NIAID).

Read More
Flex Pharma starts Phase 2 CMT trial

Flex Pharma (NASDAQ:FLKS) has initiated a Phase 2 double-blinded, parallel design trial in the U.S., known as COMMIT, to evaluate FLX-787, its co-activator of TRPA1 and TRPV1, in patients with Charcot-Marie-Tooth, who suffer from painful, debilitating cramps.

Read More
HCW ups Verastem price target to $10

Roth Capital Partners reinitiated coverage of Flex Pharma (NASAQ:FLKS) with a “buy” rating and $14 price target. The stock closed at $3.37 on Sept. 6.

Read More
BTIG starts Clementia at buy

BTIG initiated coverage of Clementia Pharmaceuticals (NASDAQ:CMTA) with a “buy” rating and 12-month price target of $32, saying the company’s lead molecule, palovarotene, presents a plethora of promising possibilities. The stock closed at $16.01 on August 30.

Read More
HCW starts Gemphire at buy

H.C. Wainwright launched coverage of Gemphire Therapeutics (NASDAQ:GEMP) with a “buy” rating and a price target of $21, saying it views the sell off in the shares following results of the ROYAL-1 clinical trial as overdone. The stock closed at $9.17 on August 30.

Read More